High-dose Ig VENA is well tolerated and efficacious in patients with multifocal motor neuropathy

Eduardo Nobile-Orazio, Dario Cocito, Chiara Briani, Rosaria Plasmati, Angelo Schenone, Francesca Gallia, Ivan Marjanovic, Anna Lotti Suffredini

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Multifocal motor neuropathy (MMN) is a rare, chronic, motor neuropathy that progressively impairs physical functioning and quality of life. Randomised controlled trials have shown that high-dose intravenous immunoglobulin (IVIg) is superior to placebo in improving muscle strength and disability, but many patients require periodic infusions to maintain long-term improvement. This observational, multicentre, retrospective study investigated the efficacy and tolerability of human normal immunoglobulin (Ig VENA) at high intravenous infusion rates in 20 MMN patients (14 male, 6 female). Thirty days after the first infusion, there was an improvement of at least 1 point in two muscles compared to baseline on the Medical Research Council (MRC) scale and of 1 point in the ONLS (Overall Neuropathy Limitation Scale) scale in 15 patients (75%) and 10 patients (50%), respectively; 45% improved on both scales. At 6 months, 100% of 12 patients had improved on the MRC and 79% of 14 patients had improved on the ONLS scale; 83% improved on both scales. All reported adverse drug reactions (ADR) were mild, transient and possibly related to the study drug. Four patients (20%) reported ADRs, three reported headache and one fever. There were no serious or unexpected ADRs. By confirming that high-dose Ig VENA is efficacious and well tolerated, this study adds to the evidence base for IVIg in MMN and potentially increases clinicians’ and patients’ choice of therapy.
Original languageEnglish
Pages (from-to)899-902
Number of pages4
JournalNeurological Sciences
Volume38
Issue number5
DOIs
Publication statusPublished - May 1 2017

Fingerprint

Intravenous Immunoglobulins
Biomedical Research
Muscle Strength
Drug-Related Side Effects and Adverse Reactions
Intravenous Infusions
Multicenter Studies
Headache
Immunoglobulins
Fever
Randomized Controlled Trials
Retrospective Studies
Placebos
Quality of Life
Muscles
Pharmaceutical Preparations
Therapeutics

Keywords

  • Efficacy
  • High dose
  • Ig VENA
  • Immunoglobulin therapy
  • Multifocal motor neuropathy
  • Tolerability

Cite this

High-dose Ig VENA is well tolerated and efficacious in patients with multifocal motor neuropathy. / Nobile-Orazio, Eduardo; Cocito, Dario; Briani, Chiara; Plasmati, Rosaria; Schenone, Angelo; Gallia, Francesca; Marjanovic, Ivan; Suffredini, Anna Lotti.

In: Neurological Sciences, Vol. 38, No. 5, 01.05.2017, p. 899-902.

Research output: Contribution to journalArticle

@article{e5bdf5979fa745c4b0adf86717ebdc2c,
title = "High-dose Ig VENA is well tolerated and efficacious in patients with multifocal motor neuropathy",
abstract = "Multifocal motor neuropathy (MMN) is a rare, chronic, motor neuropathy that progressively impairs physical functioning and quality of life. Randomised controlled trials have shown that high-dose intravenous immunoglobulin (IVIg) is superior to placebo in improving muscle strength and disability, but many patients require periodic infusions to maintain long-term improvement. This observational, multicentre, retrospective study investigated the efficacy and tolerability of human normal immunoglobulin (Ig VENA) at high intravenous infusion rates in 20 MMN patients (14 male, 6 female). Thirty days after the first infusion, there was an improvement of at least 1 point in two muscles compared to baseline on the Medical Research Council (MRC) scale and of 1 point in the ONLS (Overall Neuropathy Limitation Scale) scale in 15 patients (75{\%}) and 10 patients (50{\%}), respectively; 45{\%} improved on both scales. At 6 months, 100{\%} of 12 patients had improved on the MRC and 79{\%} of 14 patients had improved on the ONLS scale; 83{\%} improved on both scales. All reported adverse drug reactions (ADR) were mild, transient and possibly related to the study drug. Four patients (20{\%}) reported ADRs, three reported headache and one fever. There were no serious or unexpected ADRs. By confirming that high-dose Ig VENA is efficacious and well tolerated, this study adds to the evidence base for IVIg in MMN and potentially increases clinicians’ and patients’ choice of therapy.",
keywords = "Efficacy, High dose, Ig VENA, Immunoglobulin therapy, Multifocal motor neuropathy, Tolerability",
author = "Eduardo Nobile-Orazio and Dario Cocito and Chiara Briani and Rosaria Plasmati and Angelo Schenone and Francesca Gallia and Ivan Marjanovic and Suffredini, {Anna Lotti}",
year = "2017",
month = "5",
day = "1",
doi = "10.1007/s10072-017-2826-8",
language = "English",
volume = "38",
pages = "899--902",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "5",

}

TY - JOUR

T1 - High-dose Ig VENA is well tolerated and efficacious in patients with multifocal motor neuropathy

AU - Nobile-Orazio, Eduardo

AU - Cocito, Dario

AU - Briani, Chiara

AU - Plasmati, Rosaria

AU - Schenone, Angelo

AU - Gallia, Francesca

AU - Marjanovic, Ivan

AU - Suffredini, Anna Lotti

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Multifocal motor neuropathy (MMN) is a rare, chronic, motor neuropathy that progressively impairs physical functioning and quality of life. Randomised controlled trials have shown that high-dose intravenous immunoglobulin (IVIg) is superior to placebo in improving muscle strength and disability, but many patients require periodic infusions to maintain long-term improvement. This observational, multicentre, retrospective study investigated the efficacy and tolerability of human normal immunoglobulin (Ig VENA) at high intravenous infusion rates in 20 MMN patients (14 male, 6 female). Thirty days after the first infusion, there was an improvement of at least 1 point in two muscles compared to baseline on the Medical Research Council (MRC) scale and of 1 point in the ONLS (Overall Neuropathy Limitation Scale) scale in 15 patients (75%) and 10 patients (50%), respectively; 45% improved on both scales. At 6 months, 100% of 12 patients had improved on the MRC and 79% of 14 patients had improved on the ONLS scale; 83% improved on both scales. All reported adverse drug reactions (ADR) were mild, transient and possibly related to the study drug. Four patients (20%) reported ADRs, three reported headache and one fever. There were no serious or unexpected ADRs. By confirming that high-dose Ig VENA is efficacious and well tolerated, this study adds to the evidence base for IVIg in MMN and potentially increases clinicians’ and patients’ choice of therapy.

AB - Multifocal motor neuropathy (MMN) is a rare, chronic, motor neuropathy that progressively impairs physical functioning and quality of life. Randomised controlled trials have shown that high-dose intravenous immunoglobulin (IVIg) is superior to placebo in improving muscle strength and disability, but many patients require periodic infusions to maintain long-term improvement. This observational, multicentre, retrospective study investigated the efficacy and tolerability of human normal immunoglobulin (Ig VENA) at high intravenous infusion rates in 20 MMN patients (14 male, 6 female). Thirty days after the first infusion, there was an improvement of at least 1 point in two muscles compared to baseline on the Medical Research Council (MRC) scale and of 1 point in the ONLS (Overall Neuropathy Limitation Scale) scale in 15 patients (75%) and 10 patients (50%), respectively; 45% improved on both scales. At 6 months, 100% of 12 patients had improved on the MRC and 79% of 14 patients had improved on the ONLS scale; 83% improved on both scales. All reported adverse drug reactions (ADR) were mild, transient and possibly related to the study drug. Four patients (20%) reported ADRs, three reported headache and one fever. There were no serious or unexpected ADRs. By confirming that high-dose Ig VENA is efficacious and well tolerated, this study adds to the evidence base for IVIg in MMN and potentially increases clinicians’ and patients’ choice of therapy.

KW - Efficacy

KW - High dose

KW - Ig VENA

KW - Immunoglobulin therapy

KW - Multifocal motor neuropathy

KW - Tolerability

U2 - 10.1007/s10072-017-2826-8

DO - 10.1007/s10072-017-2826-8

M3 - Article

VL - 38

SP - 899

EP - 902

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 5

ER -